Trulicity ® (dulaglutid) injektion

För fullständig produktresumé för Trulicity® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Trulicity® (dulaglutid): Glykemisk kontroll

Behandling med dulaglutide resulterade i ökning av glykemisk kontroll särskilt efter morgon- och kvällsmåltider.

Detailed Information

To determine the effects of dulaglutide on glycemic excursions throughout the day, a post-hoc analysis was performed using data from

  • AWARD-1

  • AWARD-2

  • AWARD-3

  • AWARD-6

  • AWARD-8, and 

  • AWARD-9.1,2

Mean morning, midday, and evening glycemic excursions were calculated from self-monitored BG values obtained at 6- or 12-month time points.1,2

Effect of Dulaglutide on Glycemic Excursions

A significant reduction in mean glucose excursion from baseline to primary endpoint was observed in all 6 studies for patients who received dulaglutide 1.5 mg treatment (Table 1).1-3

Table 1. Glycemic Excursions from Baseline to Primary Endpointa With Dulaglutide 1.5 mg Treatment4

Glycemic Excursions, mmol/L (mg/dL)b

AWARD-1

AWARD-2

AWARD-3

AWARD-6

AWARD-8

AWARD-9

Pre-prandial

2.47±0.14
(−44.5±2.47)c

1.83±0.13
(−33.02±2.42)c

1.75±0.12
(−31.43±2.15)c

1.98±0.11
(−35.70±1.98)c

2.09±0.15
(−37.57±2.63)c

2.69±0.18
(−48.42±3.29)c

2-hour post-prandial

3.02±0.20
(−54.44±2.86)c

2.15±0.15
(−38.61±2.68)c

 

2.40±0.15
(−43.12±2.70)c

 

2.67±0.12
(−48.06±2.22)c

 

2.61±0.16  
(−47.05±2.93)c

 

3.55±0.21
(−63.94±3.80)c

Abbreviation: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes.

a Primary endpoint = 12 months for AWARD-2 and 6 months for the other five studies.

b Data presented as mean ± SE and represent change in mean of morning, midday, and evening blood glucose values from baseline to primary endpoint.

c p<.001 for the difference in glycemic excursions between baseline and endpoint.

The reduction in mean glucose excursions was primarily affected by reductions in the morning glycemic excursions and secondarily by reductions in the evening glycemic excursions.1,2

In AWARD-1, -2, and -3, the pattern of glycemic excursion reductions for dulaglutide 0.75 mg was similar to that for dulaglutide 1.5 mg. The dulaglutide 0.75-mg dose was not studied in AWARD-6, -8, and -9.1,2

References

1. Charpentier G, García-Pérez LE, Thieu VT, et al. Dulaglutide treatment reduces glycemic excursions in people with type 2 diabetes: a post-hoc analysis of six phase 3 randomized clinical trials [abstract]. Diabetes. 2017;66(suppl 1):A623. https://doi.org/10.2337/db17-2348-2482

2. Pechtner V, Charpentier G, García-Pérez LE, et al. Dulaglutide treatment reduces glycaemic excursions in people with type 2 diabetes: a post-hoc analysis of 6 phase 3 randomised clinical trials [abstract]. Diabetologia. 2017;60(suppl 1):S386. http://dx.doi.org/10.1007/s00125-017-4350-z

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4. Pechtner V, García-Pérez LE, Thieu V, et al. Dulaglutide treatment reduces glycaemic excursions in people with type 2 diabetes: a post-hoc analysis of 6 phase 3 randomised clinical trials. Poster presented at: 53rd Annual Meeting of the European Association for the Study of Diabetes; September 14, 2017; Lisbon, Portugal.

Glossary

AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes

BG = blood glucose

Datum fӧr senaste ӧversyn 2019 M02 27


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Skriv din fråga till oss